フォロー
Stijn van Beek
Stijn van Beek
Consultant, Pharmetheus
確認したメール アドレス: pharmetheus.com
タイトル
引用先
引用先
Personalized tuberculosis treatment through model-informed dosing of rifampicin
SW van Beek, R Ter Heine, RJ Keizer, C Magis-Escurra, RE Aarnoutse, ...
Clinical pharmacokinetics 58, 815-826, 2019
352019
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase …
SC van der Boor, MJ Smit, SW van Beek, J Ramjith, K Teelen, ...
The Lancet Infectious Diseases 22 (11), 1596-1605, 2022
322022
Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant tuberculosis
P Ngwalero, JCM Brust, SW van Beek, S Wasserman, G Maartens, ...
Antimicrobial agents and chemotherapy 65 (11), 10.1128/aac. 02399-20, 2021
212021
A model-informed method for the purpose of precision dosing of isoniazid in pulmonary tuberculosis
SW van Beek, R Ter Heine, JWC Alffenaar, C Magis-Escurra, ...
Clinical Pharmacokinetics 60, 943-953, 2021
142021
A new framework to implement model-informed dosing in clinical guidelines: piperacillin and amikacin as proof of concept
SJF Hartman, JGE Swaving, SW Van Beek, BD Van Groen, M De Hoop, ...
Frontiers in Pharmacology 11, 592204, 2020
132020
Pharmacogenetics of between-individual variability in plasma clearance of bedaquiline and clofazimine in South Africa
DW Haas, MT Abdelwahab, SW van Beek, P Baker, G Maartens, ...
The Journal of infectious diseases 226 (1), 147-156, 2022
122022
Model-predicted impact of ECG monitoring strategies during bedaquiline treatment
SW Van Beek, L Tanneau, G Meintjes, S Wasserman, NR Gandhi, ...
Open Forum Infectious Diseases 9 (8), ofac372, 2022
62022
Modeling the Impact of a Highly Potent Plasmodium falciparum Transmission-Blocking Monoclonal Antibody in Areas of Seasonal Malaria Transmission
JD Challenger, SW Van Beek, R Ter Heine, SC Van Der Boor, ...
The Journal of Infectious Diseases 228 (2), 212-223, 2023
52023
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
R Stemkens, V Jager, R Dawson, AH Diacon, K Narunsky, ...
Antimicrobial Agents and Chemotherapy 67 (10), e00683-23, 2023
42023
Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
SE Koele, SW van Beek, AJ van der Wekken, B Piet, MM van den Heuvel, ...
British journal of clinical pharmacology 88 (4), 1930-1934, 2022
42022
Safety, Tolerability and Plasmodium Falciparum Transmission-Reducing Activity of Monoclonal Antibody TB31F: An Open-Label, First-in-Human, Trial in Healthy …
SC van der Boor, M Smit, SW van Beek, J Ramjith, K Teelen, ...
32022
Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa
SW van Beek, EM Svensson, AB Tiono, J Okebe, U D’Alessandro, ...
Parasites & vectors 14, 1-11, 2021
32021
First-in-Human Evaluation of a Plasmodium falciparum Transmission-Blocking Monoclonal Antibody
SC van der Boor, MJ Smit, SW van Beek, J Ramjith, P Pickkers, Y Wu, ...
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE 105 (5), 204-205, 2021
22021
Combatting seasonal malaria transmission using a highly potent Plasmodium falciparum transmission-blocking monoclonal antibody
JD Challenger, SW van Beek, R Heine, SC van der Boor, GD Charles, ...
medRxiv, 2022.09. 11.22279612, 2022
12022
Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment
SE Koele, SW Van Beek, G Maartens, JCM Brust, EM Svensson
Antimicrobial agents and chemotherapy 66 (3), e01749-21, 2022
12022
MAJOR ARTICLE
JD Challenger, SW van Beek, R ter Heine, SC van der Boor, GD Charles, ...
2023
THE PUBLIC HEALTH IMPACT OF A HIGHLY POTENT PLASMODIUM FALCIPARUM TRANSMISSION-BLOCKING MONOCLONAL ANTIBODY IN SETTINGS WITH SEASONAL MALARIA TRANSMISSION
JD Challenger, SW van Beek, R ter Heine, SC van der Boor, GD Charles, ...
Model-informed pharmacological interventions against tuberculosis and …, 2022
2022
Model-informed pharmacological interventions against tuberculosis and malaria
SW van Beek
2022
A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis (February, 10.1007/s40262-020-00971-2, 2021)
SW van Beek, R ter Heine, JWC Alffenaar, C Magis-Escurra, ...
CLINICAL PHARMACOKINETICS 60 (7), 955-955, 2021
2021
P0516/# 1936: A NEW FRAMEWORK TO IMPLEMENT MODEL-INFORMED DOSING IN CLINICAL GUIDELINES: PIPERACILLIN AND AMIKACIN AS PROOF OF CONCEPT
S Hartman, J Swaving, S Van Beek, B Van Groen, M De Hoop, ...
Pediatric Critical Care Medicine 22 (Supplement 1 3S), 259, 2021
2021
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20